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Open Forum Infectious Diseases
BRIEF REPORT

IL-7 Immunotherapy in a
Nonimmunocompromised
Patient With Intractable Fungal
Wound Sepsis
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A nonimmunocompromised patient developed life-threatening
soft tissue infection with Trichosporon asahii, Fusarium, and
Saksenaea that progressed despite maximum antifungal therapies and aggressive debridement. Interleukin-7 immunotherapy resulted in clinical improvement, fungal clearance,
reversal of lymphopenia, and improved T-cell function.
Immunoadjuvant therapies to boost host immunity may be efficacious in life-threatening fungal infections.
Keywords.
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Invasive fungal infections are a growing complication following major traumatic injuries that result in extensive soft
tissue damage [1, 2]. The Department of Defense has identified
combat wound infections due to invasive fungi as an emerging
threat and a high priority [1, 2]. Despite aggressive surgical debridement and antimicrobial therapy that is active against the
particular fungal pathogens, many infections progress, with resultant substantial morbidity and/or mortality. Progression of
infection despite optimal therapy is consistent with the hypothesis that impaired host immunity may be an important pathophysiologic mechanism that renders the fungus refractory to
therapy [3, 4].

Received 29 March 2021; editorial decision 13 May 2021; accepted 21 May 2021.
a
Equal contribution
Correspondence: Richard S. Hotchkiss, MD, Department of Anesthesiology, Washington
University School of Medicine, 660 South Euclid Ave., St Louis, MO 66110 (richardshotchkiss@
wustl.edu).
Open Forum Infectious Diseases®2021
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofab256

PATIENT CASE

A previously healthy 21-year-old man presented to the hospital
after suffering a high-velocity motorcycle accident. He suffered
severe injuries including comminuted pelvic fractures, multiple
extremity factures, and a catastrophic degloving injury of the
buttocks and perineum with gross wound soilage. He also suffered vascular injuries that required angioembolization of his
bilateral iliac arteries for hemorrhage control. On postinjury day
7, he was noted to have a rapidly progressing necrotizing soft
tissue infection of his buttocks and perineum. Tissue cultures
at that time demonstrated a polymicrobial infection including
abundant Acinetobacter spp., abundant Pseudomonas spp. (not
Pseudomonas aeruginosa), and moderate Stenotrophomonas
maltophila. His wound cultures also grew Trichosporon asahii,
Saksenaea spp., and Fusarium spp. The Saksenaea isolate
was initially identified using conventional fungal identification methods and the sporulation inducement method for
Saksenaea as described by Padhye and Ajello [9]. The isolate
was then referred to Mayo Clinic (Rochester, MN, USA) for
a species-level identification, but only a genus level could be
determined. The Saksenaea isolate underwent susceptibility
testing at the University of Texas Health San Antonio using the
Clinical and Laboratory Standards Institute (CLSI) broth dilution antifungal reference method. Drug sensitivities were as follows: amphotericin B <0.03 mcg/mL, posaconazole 0.25 mcg/
mL, isavuconazole 1 mcg/mL. The Fusarium was identified by
phenotype and microscopy. Trichosporon asahii was identified
by matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS). No sensitivities were
performed on Fusarium or Trichosporon asahii.
He was aggressively treated with daily or alternating-day
operative debridement, broad-spectrum parenteral and topical antibacterial and antifungal therapy. Antimicrobial
therapy included ceftazidime, metronidazole, trimethoprimsulfamethoxazole, micafungin, amphotericin B, and
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Drugs that boost the host immune system are increasingly being tested in various infectious disorders in both immunosuppressed and immunocompetent patients. These
immune-adjuvant therapies include interferon (IFN)-γ, checkpoint inhibitors (anti–programmed cell death 1 (anti-PD-1),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
and interleukin (IL)-7 [5–8]. In some cases, these immuneadjuvant therapies have restored indices of immune function
and lead to control of refractory infections [5–8]. Herein, we
describe the use of IL-7 in a patient with life-threatening soft
tissue necrotizing fungal infection that was refractory to the
maximal available therapy.
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The patient had demonstrated persistent fungal growth
with rapidly extending tissue borders requiring surgical debridement over the course of 52 days before initiation of IL-7
(Supplementary Table 1). After initiation of IL-7 therapy, an
increasing number of tissue cultures did not identify fungal
elements, and by the fifth dose of IL-7, the patient had persistently negative cultures. Tissue histology also became negative
for fungus at approximately the same time as tissue cultures
(Figure 1E).
After completing IL-7 therapy, the wound beds qualitatively improved with development of healthy granulation tissue
facilitating skin grafting. The patient’s blood, wound, and bone
cultures were negative for bacterial or fungal pathogens for
40 days after completing IL-7 therapy (see Supplementary Table
1 for complete list of cultures). The resolution in wound fungal
infection facilitated definitive closure of >90% (>700 cm2)
of open wounds. Currently, the patient has a small region of
exposed pelvic bone and a persistent perineal wound that remains open due to disruption of his urethra and ongoing urine
drainage that is pending reconstruction. A recent biopsy of the
exposed pelvic bone and the open wound margin were positive
for Trichosporon asahii. This is being treated with an extended
course of isavuconazonium. There has been no recurrence of
the life-threatening necrotizing fasciitis that resolved with IL-7
therapy.
The effect of IL-7 in terms of improving the patient’s
T-cell function was evaluated by an ex vivo stimulation assay
using anti-CD3 and anti-CD28 antibodies (BioLegend, San
Diego, CA, USA) on an IFN-γ ELISPOT assay (Cellular
Technologies Limited, Shaker Heights, OH, USA), which
was performed as previously described [10, 11]. The total
number of activated, IFN-γ-producing T cells progressively
increased from baseline (before IL-7 therapy), accompanied
by a 1.4-fold increase in the proportion of activated T cells
(Figure 1D).
A beneficial effect of IL-7 in infectious disorders is to increase
expression of lymphocyte adhesion molecules and induce lymphocyte trafficking to sites of infection [6]. Consequently,
immunohistochemical staining using the lymphocyte marker
anti-CD3 was performed and demonstrated a marked increase
in the number of lymphocytes in the biopsies from the infected
wound (Figure 1F, right-hand panel).
To measure the specific molecular effects underlying the
increased T-cell responsiveness induced by IL-7, we measured intracellular levels of phospho-STAT5 (pSTAT5) in CD4
and CD8 T cells using mass cytometry. STAT5 is the primary
T-cell differentiation signal downstream of the IL-7 receptor
[12]. T cells were identified based on surface marker staining
(CD45+/CD15-/CD66b-/CD56-/CD3+). We then measured the pSTAT5 signal intensity. IL-7 was associated with a
3-fold increase in activated STAT5 in CD4-T cells and a 2-fold
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posaconazole (Figure 2), as well as VERAFLO vac instillation of antimicrobials into the wound bed. The patient’s
polymicrobial soft tissue infection continued to advance and
was accompanied by multisystem organ failure and shock.
Over a 4-week period, he required debridement of >3000 cm2
of skin, subcutaneous tissue, and muscle involving the entire perineum, bilateral thighs, buttocks, and circumferential
abdominal wall (Figure 1B). Although bacterial pathogens
were rapidly eradicated from the patient’s wound, cultures
were persistently positive for both Trichosporon asahii and
Saksenaea species despite triple antifungal therapy consisting of posaconazole, amphotericin B, and micafungin.
Histopathological exam of wound biopsies showed invasive
fungal elements (Figure 1E).
Despite aggressive antimicrobial and surgical management over the course of 7 weeks after the identification of the
polymicrobial infection, his condition continued to worsen.
The patient initially had an increased lymphocyte count of up
to 2×103/µL, but soon developed persistent lymphopenia with
neutrophilia as high as 50×103/µL. Therefore, immune-adjuvant
therapy with recombinant human IL-7 was considered. IL-7
induces proliferation, maturation, and activation of CD4 and
CD8 T cells, which are severely depleted and poorly functional
in patients with life-threatening infections including those due
to fungal pathogens [6, 7].
Informed consent was obtained from the patient and family,
and a test dose of IL-7 (3 µg/kg ideal body weight, intramuscularly; kindly provided by Dr. Michel Morre, RevImmune)
was administered on day 59 postinjury, which was well tolerated (Figure 1A). Twenty-four hours later, the dosage was increased to 10 µg/kg and continued every 3–4 days for 7 doses.
The patient’s clinical status showed significant improvement
beginning at 4–7 days after initiation of IL-7. As illustrated by
serial pictures of the wound, the most notable change following
initiation of IL-7 was to slow the progression of the invasive soft
tissue necrosis (Figure 1B, green arrows).
In addition to decreased infectious spread and fungal
proliferation, with improved wound healing and healthierappearing tissue margins, clinical indicators of severity of disease improved within days of IL-7 treatment initiation with
improvement of the fever curve, tachycardia, and tachypnea
(Supplementary Figure 1). Laboratory evidence of resolution
of the fungal invasion included progressive decreases in total
white blood cell count and increasing absolute lymphocyte
counts (Figure 1A). The patient’s absolute lymphocyte count
increased >6-fold from a low of 600 lymphocytes/µL to >4000
lymphocytes/µL (upper limit of normal for absolute lymphocyte counts is 3500). Of note, the increase in the patient’s absolute lymphocyte count was likely due to both the effect of IL-7
in inducing lymphocyte proliferation and to the resolution of
the fungal infection.
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Figure 1. Serial clinical, anatomic, immunologic, and pathologic changes in an IL-7-treated patient with invasive fungal infection. A, Changes in WBC and ALC during the
patient’s hospital course. Days of hospitalization are indicated on the x-axis; IL-7 was initiated on day 59. Red arrows identify administration of IL-7. B, Color photographs of
lower back and gluteal region demonstrating necrotic and infected areas; there was serial progression of the infection with necrotic regions, which resolved following initiation of IL-7. The green arrows in the second photo from the left show necrotic and poorly perfused margins. C, IL-7 mediates its effects to increase T-cell IFN-γ production
via STAT5 signaling. CyTOF demonstrated that there was a doubling of STAT5 expression in lymphocytes obtained after initiation of IL-7 compared with pretreatment; CyTOF
data are reported at the geometric mean raw signal intensity for the gated population. All 3 samples were barcoded and run in a single experiment. The data presented are
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increase in CD8-T cells (Figure 1C). These data provide a putative molecular mechanism for the increase in T-cell function
induced by IL-7.

Patient Consent

Informed consent was obtained from the patient and the
patient’s parents for therapy using IL-7 and for publication of
this case report including images of the patient’s wounds.

DISCUSSION

the geometric mean of the raw values for the gated populations (not normalized), as reported by the cytometer. D, Decreased T-cell IFN-γ production is a hallmark of T-cell
exhaustion; ELISpot analysis on PBMCs were performed serially; the far-left ELISpot well had 47 IFN-γ-producing lymphocytes (depicted as SFU) per 1000 lymphocytes plated;
the middle and far-right wells show a progressive increase in the both the number of lymphocytes in the PBMC fraction as well as an increase in the proportion of active IFNγ-producing lymphocytes following CD3/CD28 stimulation. E, Immunohistochemical staining of wound margins: left panel: Gomori’s methanamine silver stain highlighting
invasive fungal hyphae (arrows), 400×; middle panel: hematoxylin and eosin stain showing necroinflammatory debris and refractile-appearing fungal hyphae (arrows), 400×;
right panel: Gomori’s methanamine silver stain highlighting shows clearance of invasive fungal microorganisms following IL-7 treatment; soft tissue necrosis is present, 400×.
F, Immunohistochemical staining for CD3+ T cells. Note the marked increase in the number of lymphocytes in the wound margins that occurred after initiation of IL-7, 100×.
Abbreviations: ALC, absolute lymphocyte count; CyTOF, time of flight mass cytometry; IFN-γ, interferon-γ; IL-7, interleukin-7; PBMCs, peripheral blood mononuclear cells;
SFU, spot-forming units; WBC, white blood cell count.
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Critically ill patients with protracted sepsis typically develop profound and persistent immunosuppression [13].
Numerous pathophysiologic mechanisms drive the immune
suppression including apoptosis-induced lymphocyte depletion, increased myeloid-derived suppressor cells, and T-cell
exhaustion. Based upon a growing number of case reports,
there is increasing recognition that therapies that boost patient immunity may be beneficial in patients with intractable
infections that are nonresponsive to conventional therapies
[5, 8, 13]. Particularly relevant to the present case is the use
of the immune-adjuvants nivolumab (anti-PD-1) and IFN-γ
in a Belgian bomb blast victim who was dying of refractory
mucormycosis [5]. Immune-adjuvant therapy resulted in
rapid clinical improvement, enhanced immune phenotypic
markers, and fungal elimination.
Although a number of immuno-adjuvants are likely to be
beneficial, IL-7 is particularly attractive because of its effects
on a broad array of immune effector cells including CD4 and
CD8 T cells, mucosally associated invariant T cells, and innate
lymphoid cells that play key roles in pathogen elimination [8,
13]. Although not presently approved for clinical use, IL-7 is
under investigation in multiple clinical trials in infectious and
oncologic disorders [6–8]. IL-7 has an excellent safety profile
and has been used in >450 patients with both severe infections
and various cancers. A double-blind, randomized, phase 2 trial
of IL-7 in patients with sepsis showed that IL-7 was well tolerated, reversed sepsis-induced lymphopenia, and enhanced
T-cell activation [6]. IL-7 has also been shown to prevent lymphocyte apoptosis, improve immune function, and increase

survival in a 2-hit animal model of fungal sepsis. IL-7’s primary effect is on lymphocytes, but it will have indirect effects
to enhance macrophage and neutrophil antimicrobial properties as well. IL-7 increases T-cell production of IFN-γ, a potent activator of macrophages. IL-7 also increases T-cell IL-17
production, which plays a critical role in fungal infections by
enhancing neutrophil migration to sites of infection [6]. IL-7
should be particularly advantageous in patients with profound
and persistent lymphopenia because of its potential to prevent
lymphocyte apoptosis and induce lymphocyte proliferation.
Although the patient in this report had no history of recurrent fungal infections to suggest an underlying immune deficiency, persistent or recurrent mucocutaneous or invasive
fungal infections developing in a “normal” host may be indicative of genetic defects in innate or adaptive immunity [14, 15].
Recently, defects in the caspase recruitment domain containing
protein 9 (CARD9) have been reported to occur in patients with
severe fungal infections [15].
Recently, immuno-adjuvant therapy to boost host immunity has been proposed as a potential additional powerful
weapon in the armamentarium in infectious diseases [8]. The
authors believe that the rather remarkable turnaround in the
patient’s hospital course in the current report provides further support for the concept of augmenting the integrity of
the host immune system in life-threatening infections. The
ability to evaluate the functional status of the patient’s immune system, such as the use of the ELISpot assay in the
present case (Figure 1D), will greatly advance this field by
identifying patients who are immunosuppressed and enabling
investigators to follow patient response to immuno-adjuvant
therapies. Patients with intractable hospital-acquired infections involving multidrug-resistant bacteria or patients
with invasive fungal infections are likely good candidates
for immuno-adjuvant therapies because they are almost invariably immunosuppressed and have high mortality. Use
of IL-7, checkpoint inhibitors, or other immune-adjuvant
therapies might be considered on a compassionate basis in
patients dying of these intractable fungal infections. If immunotherapy does prove to be an effective new approach in
infectious diseases, it could usher in a novel path forward in
the battle against increasingly deadly foes.
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Figure 2. Time course of antimicrobial and surgical therapy. Graphical depiction of a timeline from the date of admission through the fourth month of his hospital course.
This timeline demonstrates the surgical debridement occurrences, positive tissue cultures, antimicrobial therapies, and doses of recombinant human IL-7. Abbreviation: IL-7,
interleukin-7.
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